It is expected that the usual dose of canadian rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Four published clinical trials have assessed the efficacy and safety of rimonabant in the treatment of obesity and cardiometabolic risk factors. Other studies of the drug have been presented as posters at clinical meetings, but they are not reviewed in this article.
The iSmonabant In Obesity (RIO) Program consists of four published clinical trials comparing rimonabant [...]

Rimonabant [,/V-piperino-5-(4-chloro-phenyl)-1-1(2,4-dichlorophenyl)-4-meth-ylpyrazole-3-carvoxamide] is a CB1 antagonist. At low concentrations, it may also act as an inverse agonist.8 At very high concentrations, canadian rimonabant also behaves as a CB2 receptor antagonist, blocks calcium and potassium channels, and may directly affect cellular gap junctions.
Cannabinoid receptors are members of the G-protein coupled receptor (GPCR) superfamily of cell-surface heptahelical [...]

INTRODUCTION
The prevalence of obesity continues to rise. Current data indicate that the combined prevalence of overweight and obesity in adults in the U.S. is 66.3%. The prevalence for obesity alone in adults is 32.2%; for extreme obesity in adults, this figure is 4.8%. Approximately 17.1% of children and adolescents in the U.S. are overweight. Overweight [...]